No Data
No Data
Stella Pharma: Supplementary materials for the first quarter financial results of the March 2025 period.
Stella Pharma: Q1 financial report for the period ending March 2025 (Japan Standard) (Non-consolidated)
Daiwa House, Mazda, NTT, Softbank Group (7th)
※The above calendar is tentative and subject to change due to company circumstances. --------------------------------------- August 7th (Wednesday) <1451> KHC <1719> Ando Hazama <1720> Tokyu Construction <1726> BRHD <1762> Takamatsu G <1833> Okumura Group <1835> Tokei Kogyo <1890> Toyo Construction <189
The TOPIX 250 Index on the Tokyo Stock Exchange's Growth Market fell for the third day in a row, with Timely experiencing a temporary offer price decline.
Tokyo Stock Exchange Growth Market Index 833.99 -9.32 / Volume 0.3 billion 27.02 million shares / Trading value 105.9 billion yen. Tokyo Stock Exchange Growth Market 250 Index 646.37 -8.65 / Volume 0.1 billion 84.45 million shares / Trading value 58.7 billion yen. Today's growth market, both Tokyo Stock Exchange Growth Market Index and Tokyo Stock Exchange Growth Market 250 Index, fell for the first time in 3 days. Number of rising stocks is 196, number of falling stocks is 338, and unchanged stocks is 42. The US stock market on the 29th was mixed. The Dow Jones Industrial Average was up 49.41 dollars.
Ribomic, Stella Pharma, and others.
<3070> Issuance of new shares through Amagasa third-party allocation (6 million shares), issuance of the 4th subscription rights (potential shares of 18 million shares, amount raised of approximately 0.936 billion yen) <4591> Ribomic signs joint research agreement with University of Tokyo on ophthalmic diseases <4888> Stella Pharma, large exercise of the 4th subscription rights (with revision clause for exercise price), delivery of 0.534 million 4000 shares from 12th <9235> Introducing shareholder benefits program for Net Advertisement sales
Glad Cube, C&S, and others.
<3479> Revision above, expected operating profit for this term is 8.2 billion yen ← 7.35 billion yen. <4076> Established medium-term management plan for the term from May 25, 2027 to May 25, 2027, with a sales target of 10 billion yen for the term ending May 25, 2027. <4883> Mass exercise of 12th new share subscription rights (with exercise price adjustment clause) from Modalis, the number of shares to be awarded from the 11th, 0.85 million shares. Large-scale exercise of the first unsecured convertible bond type new share subscription rights with conversion price adjustment clause, with the number of shares to be awarded from the 3rd, 1.42 million 8568 shares.
No Data